ACVRL1 drives resistance to multitarget tyrosine kinase inhibitors in colorectal cancer by promoting USP15-mediated GPX2 stabilization.

Xiaolin LuRuiqi LiuYuanyu LiaoLuying CuiHaoxiu SunDongzhi ZhangBojun WangLin FangXin GuanYuanfei YaoChao LiuYan-Qiao Zhang

Published in: BMC medicine (2023)

Our results demonstrate that the Wnt/β-catenin/KCNQ1OT1/miR-7-5p/ACVRL1/GPX2 biological axis plays a vital role in CRC, targeting which may be an effective approach for overcoming mTKI resistance.

Keyphrases

cell proliferation
stem cells
epithelial mesenchymal transition
cancer therapy
drug delivery